Organogenesis Holdings Inc   (ORGO)
Other Ticker:  
Price: $2.7300 $0.18 7.059%
Day's High: $2.73 Week Perf: 4.2 %
Day's Low: $ 2.51 30 Day Perf: 19.21 %
Volume (M): 939 52 Wk High: $ 4.50
Volume (M$): $ 2,564 52 Wk Avg: $2.78
Open: $2.57 52 Wk Low: $1.80

 Market Capitalization (Millions $) 363
 Shares Outstanding (Millions) 133
 Employees 896
 Revenues (TTM) (Millions $) 456
 Net Income (TTM) (Millions $) 9
 Cash Flow (TTM) (Millions $) -23
 Capital Exp. (TTM) (Millions $) 36

Organogenesis Holdings Inc
Organogenesis Holdings Inc is a globally recognized healthcare company that operates in the regenerative medicine and biomaterials industries. The company was founded in 1985 and is headquartered in Canton, Massachusetts. Organogenesis is committed to providing innovative solutions for wound healing, tissue regeneration, and surgical products that enhance the standard of care for patients globally.

Organogenesis Holdings focuses on developing products that are biologically-based and offer regenerative properties to promote healing and restoration of damaged tissues. The products developed by the company are based on advanced scientific research that integrates biological and physical factors to create a unique bioengineering product. The three main areas of focus for Organogenesis are Advanced Wound Care, Surgical & Sports Medicine, and Orthobiologics.

Advanced Wound Care is the primary focus of the company, and it offers an extensive product line to aid in the process of wound healing. The products developed for Advanced Wound Care include Apligraf, a bioengineered living cell product that aids in the healing of diabetic foot ulcers, venous leg ulcers, and pressure sores, and Dermagraft, a bioengineered dermal substitute that offers the ability to restore tissue for the treatment of chronic wounds.

Organogenesis Holdings aims to provide innovative surgical and sports medicine solutions for tissue repair, restoration, and healing. The company's products in this category include NuShield, a xenogenic tissue matrix that provides a barrier to soft tissue, and Allosync, a product that aids in the re-building of damaged cartilage.

Orthobiologics is a focus area of Organogenesis, and the company offers products that provide support and restoration for bone tissue. The products in this category include Gintuit, a product that is used for tissue regeneration and restoration, and NuCel, which is used for bone grafting and repair.

Organogenesis also places a great deal of focus on research and development to ensure that it remains at the forefront of the regenerative medicine industry. The company's R&D team is responsible for exploring new technologies and techniques that can be used to develop new products that offer better results to patients.

In conclusion, Organogenesis Holdings Inc is a leading healthcare company that is committed to research, development, and innovation in the regenerative medicine and biomaterials industries to ensure that it provides optimal solutions for tissue restoration and healing for patients globally.

   Company Address: 85 Dan Road Canton 2021 MA
   Company Phone Number: 575-0775   Stock Exchange / Ticker: NASDAQ ORGO
   ORGO is expected to report next financial results on February 29, 2024.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Conduit Pharmaceuticals Inc

Conduit Pharmaceuticals Inc. Records Operating Shortfall in Q3 2023 but Reveals Promising Financial Indicators

As the earnings cycle for the third quarter of 2023 unfolds, various industries are reporting their financial results. One notable sector is Major Pharmaceutical Preparations, with Conduit Pharmaceuticals Inc being among the corporations announcing its numbers. Despite the absence of realized products and services, the company reported an operating shortfall of $-1.069 million during the July to September 30, 2023 period. However, a closer look at the financials reveals positive indicators, including a significant increase in net profits compared to the previous year. This article aims to analyze and contextualize the financial results of Conduit Pharmaceuticals Inc.
Financial Performance and Stakeholder Expectations:
During the current reporting period, Conduit Pharmaceuticals Inc faced an operating shortfall of $-1.069 million. This unfavorable figure, suggesting a loss for the company, signals the need for additional revenue sources to be explored as soon as possible. However, despite the current financial challenges, stakeholders seem less concerned about the organization's operational excellence and recent developments.

Ayala Pharmaceuticals Inc

ADXS Surpasses Expectations with Strong Third Quarter Results, Drives Optimism in the Pharmaceutical Industry

In the Major Pharmaceutical Preparations industry, where large companies dominate the market, smaller players are making their presence felt with promising results. One such company worth noting is ADXS, which recently announced an operating loss of $-7.131 million for the third quarter of 2023?a significant improvement compared to the same period last year, when the loss was $-7.291 million.
ADXS's positive results come as welcome news, particularly given the lack of easier references in the industry. This performance has generated optimism among market observers, who are now eyeing ADXS as a potential investment opportunity. The company's relentless pursuit of diverse corporate strategies aimed at ensuring new revenue streams has further bolstered this confidence.

Anebulo Pharmaceuticals Inc

Anebulo Pharmaceuticals Inc Achieves Promising Improvement, Reporting Operating Loss of $-2.543678 Million in Q1 2024

Anebulo Pharmaceuticals Inc, a lesser-known player in the Major Pharmaceutical Preparations sector, recently published their financial numbers for the first quarter of 2024. In a positive surprise for investors and analysts, the company announced that it had realized an operating loss of -$2.543678 million, an improvement from the previous year's operating loss of -$2.612047 million.
What is particularly noteworthy about this improvement is the decrease in diminishing returns, from -$2.612 million in the first quarter of 2023 to -$2.481 million in the same period this year. This suggests that Anebulo Pharmaceuticals Inc is making progress towards becoming an exceptional company in the Healthcare sector.

Qualigen Therapeutics Inc

Lackluster revenue at the Qualigen Therapeutics Inc in the most recent fiscal period

Qualigen Therapeutics Inc stock has seen some fluctuations in recent trading days. However, over the last five trading days, the stock experienced a solid gain of 7.2%. This positive movement comes after a slight decline of -1.91% during the preceding month.
Investors may also note that Qualigen Therapeutics Inc stock is currently trading only 12.3% above its 52-week low. This suggests that the stock has not seen significant upward momentum in recent months.

Onconova Therapeutics Inc

A deficit of $-0.23 per Share at the Onconova Therapeutics Inc amid the fiscal third quarter of 2023

Onconova Therapeutics Inc (ONTX) has recently reported its fiscal third-quarter results for 2023, and the numbers are not looking promising for the biopharmaceutical company. The company's financials reveal a decrease in earnings per share (EPS) compared to the same quarter last year, as well as a surge in deficit from the previous quarter.
For the fiscal third quarter of 2023, ONTX reported a loss of $-0.23 per share, which is slightly better than the loss of $-0.26 per share reported a year ago. However, compared to the previous quarter, the deficit has increased from $-0.20 per share. This indicates a concerning trend of worsening financial performance for the company.


Organogenesis Holdings Inc's Segments
• View Complete Report


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2023 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com